

Modulation of liver mitochondrial NOS is implicated in thyroid-dependent regulation of O₂ uptake

MARÍA CECILIA CARRERAS,¹ JORGE G. PERALTA,¹ DANIELA P. CONVERSO,¹
PAOLA V. FINOCCHIETTO,¹ INÉS REBAGLIATI,² ANGEL A. ZANINOVICH,²
AND JUAN JOSÉ PODEROSO¹

¹Laboratory of Oxygen Metabolism and ²Nuclear Medicine Center, University Hospital, University of Buenos Aires, 1120 Buenos Aires, Argentina

Received 7 May 2001; accepted in final form 3 August 2001

Carreras, María Cecilia, Jorge G. Peralta, Daniela P. Converso, Paola V. Finocchietto, Inés Rebagliati, Angel A. Zaninovich, and Juan José Poderoso. Modulation of liver mitochondrial NOS is implicated in thyroid-dependent regulation of O₂ uptake. *Am J Physiol Heart Circ Physiol* 281: H2282–H2288, 2001.—Changes in O₂ uptake at different thyroid status have been explained on the basis of the modulation of mitochondrial enzymes and membrane biophysical properties. Regarding the nitric oxide (NO) effects, we tested whether liver mitochondrial nitric oxide synthase (mtNOS) participates in the modulation of O₂ uptake in thyroid disorders. Wistar rats were inoculated with 400 μCi ¹³¹I (hypothyroid group), 20 μg thyroxine (T₄)/100 g body wt administered daily for 2 wk (hyperthyroid group) or vehicle (control). Basal metabolic rate, mitochondrial function, and mtNOS activity were analyzed. Systemic and liver mitochondrial O₂ uptake and cytochrome oxidase activity were lower in hypothyroid rats with respect to controls; mitochondrial parameters were further decreased by L-arginine (–42 and –34%, *P* < 0.05), consistent with 5- to 10-fold increases in matrix NO concentration. Accordingly, mtNOS expression (75%) and activity (260%) were selectively increased in hypothyroidism and reverted by hormone replacement without changes in other nitric oxide isoforms. Moreover, mtNOS activity correlated with serum 3,5,3'-triiodothyronine (T₃) and O₂ uptake. Increased mtNOS activity was also observed in skeletal muscle mitochondria from hypothyroid rats. Therefore, we suggest that modulation of mtNOS is a substantial part of thyroid effects on mitochondrial O₂ uptake.

hypothyroidism; oxygen uptake regulation; hyperthyroidism

BASAL METABOLIC RATE and systemic O₂ uptake are representative parameters of the energy cost of living for endotherms and exotherms. At thermoneutral environment, most of the resting O₂ uptake is consumed in the mitochondrial synthesis of ATP to provide energy to cell pumps and biosynthetic metabolism. However, some energy is dissipated to counteract the proton back flow not involving ATP synthesis in the mitochondrial inner membrane (proton leak), partly depending on the existence of protonmotive force (electrochemical poten-

tial difference from protons across the inner membrane) and partly as an intrinsic property of mitochondrial membranes (5, 19).

Resting O₂ uptake and basal metabolic rate are typically regulated by the thyroid state; hypothyroidism and hyperthyroidism are opposite conditions associated to decreased and increased basal O₂ uptake, respectively (16, 22). Thyroid hormone effects are exerted on the mitochondria of specific target tissues such as the liver and skeletal muscle, the most important O₂ consumers, whereas oxidative metabolism of other organs such as the brain is not affected (26).

The action of thyroid hormone on respiratory functions has been considered to be operating at two levels: by altering mitochondrial inner membrane composition and permeability and by influencing respiratory gene expression. Changes in properties and composition of mitochondrial membranes, particularly in cardiolipin content, lead to variations of redox enzyme activities (19, 29) and in proton leak (5). Activation or inhibition of nuclear gene transcription by 3,5,3'-triiodothyronine (T₃) bound to nuclear thyroid receptors has been related to transcriptional changes in the expression of some genes encoding components of the respiratory chain like cytochrome *c*₁ and F₁-ATPase (22). Nevertheless, changes on the nuclear signaling pathway or in the expression of redox enzymes are not consistently found (22).

On the other hand, in the last years, it has been reported by different research groups (7, 8, 23, 33) that nitric oxide (NO) regulates mitochondrial O₂ uptake by a high affinity and reversible binds to the Cu²⁺ center of cytochrome oxidase. Inhibition of cytochrome oxidase activity depends on the O₂-to-NO ratio (3) and represents an important adaptive response to changes in blood flow (4, 24). Accordingly, activation of endothelial NO synthase (eNOS) by bradykinin induces a prompt decrease in myocardial O₂ uptake (24).

The recent finding of a distinct NOS in rat liver mitochondria (mtNOS) by independent groups (12, 13) added a new perspective on the regulation of mitochon-

Address for reprint requests and other correspondence: M. C. Carreras, Laboratory of Oxygen Metabolism, Univ. Hospital, Univ. of Buenos Aires, Cordoba 2351, 1120 Buenos Aires, Argentina (E-mail: jpoderos@fmed.uba.ar).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

drial functions. The mtNOS releases NO vectorially into the mitochondrial matrix, a cellular differentiated compartment; in this context, effects of NO on the components of the electron transfer chain, particularly on cytochrome oxidase, are amplified. By this mean, mtNOS may finely modulate mitochondrial O₂ uptake in the presence of its substrate L-arginine (L-Arg) (4).

Recently, a report was focused on the regulation of NOS expression by thyroid hormones (11). Furthermore, we hypothesized here that, in target tissues like the liver, thyroid-dependent regulation of O₂ uptake selectively involves the modulation of mtNOS. Likewise, the thyroid-dependent variations in basal metabolic rate should include the correlative percentage of NO-dependent inhibition of mitochondrial O₂ uptake.

EXPERIMENTAL PROCEDURES

Experimental design. Wistar rats (230–280 g body wt) were divided in three major groups: a hypothyroid group that was injected intraperitoneally with a single dose of ¹³¹I (400 μCi/100 g body wt), a hyperthyroid group that was daily injected subcutaneously with 20 μg thyroxine (T₄)/100 g body wt over 2 wk, and the control group. The hypo- and hyperthyroid state was confirmed by T₃ blood analysis after 30 and 15 days of treatment. To return rats to the euthyroid state, a subgroup of hypothyroid rats was injected subcutaneously with T₄ (2 μg/100 g body wt) for 3–6 consecutive days.

Systemic O₂ consumption. Whole animal O₂ consumption was measured in an open circuit. Room air was drawn into the chamber and released through the outflow opening. The effluent gas from the chamber was sampled with a vacuum pump, drawn through anhydrous CaSO₄ and into an O₂ analyzer (OM-14 Beckman Instruments), and into a CO₂ analyzer (Godart Statham; NV Bilthove, Holland) set in series. Consumption was calculated from the measured flux through the chamber, the expired fractions of effluent O₂ and CO₂ in room air, the air temperature, and barometric pressure. Expired gases were corrected to standard temperature, pressure, and dry weight. Measurements were done by triplicate after a 30-min habituation period. O₂ uptake was corrected to lean body mass [expressed as ml O₂/(min·body mass^{2/3})] to avoid the effects of body mass variations of the studied groups on resting metabolic rates, as previously described (20).

Isolation and purification of rat liver mitochondria. Excised liver tissue samples (mean weight 4 g) were placed in an ice-cold homogenization medium consisting of 0.23 M mannitol, 70 mM sucrose, 10 mM Tris·HCl, 1 mM EDTA, 5 μg aprotinin, 100 μg/ml phenylmethylsulfonyl fluoride with 0.5% bovine serum albumin, pH 7.4. Mitochondria from the gastrocnemius muscle were isolated in Chappell-Perry buffer in the presence of antiproteases. Tissues were finely minced and transferred to a Teflon, motorized, Potter-Elvehjem homogenizer (Thomas Scientific; Philadelphia, PA) and homogenized in 8 ml of cold homogenization buffer per gram of tissue. The homogenate was centrifuged at 700 g at 4°C for 10 min. The supernatant was decanted and centrifuged at 7,000 g for 10 min (2). The mitochondrial pellet was further purified using Percoll gradient to completely remove contaminating organelles and broken mitochondria (18). Briefly, mitochondria were resuspended in 30% Percoll in 225 mM mannitol, 70 mM sucrose, 1 mM EGTA, 25 mM HEPES, and 0.1% bovine serum albumin (MSHE). The solution was spun at 95,000 g for 30 min, and the ring with a density of 1.025–1.075 g/ml was collected and washed twice with

MSHE to remove Percoll, twice with 150 mM KCl to remove attached proteins like arginase, followed by two washings with MSHE without BSA. Mitochondria were finally resuspended to 30 mg of protein/ml.

Mitochondrial respiratory activities and respiratory control ratio. Oxygen uptake was determined polarographically with a Clark-type electrode placed in a 3-ml chamber at 30°C, in reaction medium consisting of 0.23 M mannitol, 70 mM sucrose, 30 mM Tris·HCl, 4 mM MgCl₂, 5 mM Na₂HPO₄·KH₂PO₄, and 1 mM EDTA, pH 7.4, saturated with room air (225 μM O₂) with 0.5–1 mg mitochondria protein/ml. Oxygen uptake was determined with 6 mM malate-glutamate as substrates in the presence (state 3) or the absence (state 4) of phosphate acceptor (0.2 mM ADP). Oxygen uptake was expressed in nanogram atoms oxygen per minute per milligram of protein. Respiratory control rate was calculated as state 3/state 4 respiration rate. The P/O ratio was calculated as the ratio of nmoles of added ADP per nanogram atoms of O₂ utilized during state 3 (10). Supplementation of 0.3 mM L-Arg with or without 3 mM N^G-nitro-L-arginine (L-NMMA) to the reaction medium was performed immediately before the mitochondrial protein (1 mg/ml) addition. As previously reported (12), L-NMMA resulted particularly suitable for the analysis of mtNOS-dependent effects on mitochondrial O₂ uptake.

Cytochrome oxidase activity. Enzyme activity was determined by monitoring the oxidation of reduced cytochrome *c* in a Hitachi U-3000 spectrophotometer at 550 nm; ε₅₅₀ = 21 mM⁻¹·cm⁻¹ (31). Cytochrome *c* was reduced with potassium ascorbate that was removed afterward by eluting through a Sephadex G-25 column with potassium phosphate buffer (10 mM), pH 7.4. Cytochrome oxidase activity was determined in the mitochondria (50 μg/ml) preincubated for 2 min with or without NOS substrate (0.1 mM L-Arg) or inhibitor (1 mM aminoguanidine). The reaction was initiated by addition of 50 μM cytochrome *c*, and the rate of cytochrome *c* oxidation was determined as a pseudo-first-order reaction constant (*k'*) [expressed as *k'*(min⁻¹)·mg protein⁻¹].

Mitochondrial protein determination. Protein concentration was determined by the Lowry assay using bovine serum albumin as standard.

Western blot analysis. Proteins (50 μg/lane) were separated by electrophoresis on 7.5% SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were incubated with a rabbit polyclonal IgG anti-mouse inducible NOS (iNOS) antibody (1:500) or anti-eNOS (1:1,000). Membranes were blotted with a donkey anti-rabbit IgG (1:3,000) conjugated to horseradish peroxidase, followed by detection of immunoreactive proteins by a chemiluminescence system. Liver homogenates of lipopolysaccharide-treated rats were used as a iNOS-positive control, and rat diaphragm homogenates were used as a eNOS-positive control (1). Quantification of bands was performed by digital image analysis using a Hewlett-Packard scanner and Totalab analyzer software (Nonlinear Dynamics, Biodynamics).

NOS activity. NOS activity was determined by the conversion of L-[³H]arginine to L-[³H]citrulline (21). The reaction medium consisted of 0.1 μM L-[³H]arginine, 50 μM L-arginine, 0.1 mM NADPH, 0.3 mM CaCl₂, 0.1 μM calmodulin, 10 μM BH₄, 1 μM FAD, μM flavinmononucleotide, 50 mM L-valine in 50 mM potassium phosphate buffer (pH 7.5), and 0.1 mg of mitochondrial protein. The radiolabel present in the NOS inhibitor blank (2 mM aminoguanidine for liver mtNOS and 2 mM L-NMMA for eNOS and skeletal muscle mtNOS) was subtracted from that present in the other incubations to leave the radiolabel corresponding to NOS-dependent citrulline formation.

Serum T₃. Hormone levels were measured by RIA using a commercial kit (Diagnostic Products; Los Angeles, CA). Corrections were made for the difference in nonspecific binding derived from different plasma binding between humans and rat as previously described (34).

Statistical analysis. Data are expressed as means \pm SE. To assess statistical differences, the data were analyzed by ANOVA and the Dunnett's test or unpaired Student's *t*-test as corresponded. Data correlations were analyzed by simple linear regression. Statistical significance was accepted when $P < 0.05$.

Materials. SDS, glycerol, 2-(β -mercaptoethanol), and bromophenol blue were obtained from Bio-Rad (Richmond, CA). L-[³H]arginine was from NEN-DuPont (Boston, MA). The antibody against iNOS was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Western blotting detection system and Hybond-ECL membranes were purchased from Amersham Pharmacia Biotech. Other chemicals and biochemicals were purchased from Sigma (St. Louis, MO).

RESULTS

Thyroid status regulates systemic and mitochondrial O₂ uptake. Systemic O₂ consumption was decreased in the hypothyroid group by -30% , and it was partially reverted to -13% of control values by T₄ treatment, whereas the hyperthyroid rats showed an increase in O₂ uptake of $\sim 20\%$ (Table 1). Accordingly, state 4 (without ADP) and state 3 (with ADP) respiratory rates of liver mitochondria from hypothyroid rats were decreased, compared with control rat mitochondria, by -16% (nonsignificant) and -30% ($P < 0.05$), respectively, and returned back to control values after replacement with T₄ treatment. In opposite, in hyperthyroid rats, state 4 and 3 rates significantly increased 47 and 35%, respectively ($P < 0.05$). No differences were found in respiratory control rate or P/O ratio, supporting the efficiency of the oxidative phosphorylation of the respiratory chain in all the studied conditions.

MtNOS activity is modulated by thyroid hormone state. The activity of mtNOS was markedly modulated by thyroid status. Hypothyroid rats showed two- to fourfold increased L-[³H]citruilline production by liver mitochondria that were reverted by T₄ treatment (Fig. 1A). In accord, mtNOS activity was markedly diminished in the hyperthyroid group with respect to the control one.

The increase in liver mtNOS activity in hypothyroidism was associated with an increase in the expression of the enzyme as evaluated by Western blot analysis




Fig. 1. Modulation of liver mitochondrial nitric oxide synthase (NOS) (mtNOS) activity and expression by thyroid status. **A:** NOS activity from purified rat liver mitochondria was measured by the conversion of L-[³H]arginine to L-[³H]citruilline. Each group consisted of 6–10 samples measured by duplicate. Con, control; Hyp, hypothyroidism; Hyper, hyperthyroidism. **B:** liver mtNOS expression. Densitometry is shown as means \pm SE from 6 independent experiments. **Bottom:** representative Western blot; C corresponds to inducible NOS (iNOS)-positive control. T₄, thyroxine. * $P < 0.05$ by ANOVA and Dunnett's test.

Table 1. Regulation of systemic and liver mitochondrial oxygen uptake by thyroid status

	Control	Hypothyroidism	Hypothyroidism + T ₄	Hyperthyroidism
Serum T ₃ levels, ng/dl	62 \pm 5	39 \pm 3*	61 \pm 12	118 \pm 10*
Systemic O ₂ uptake, ml O ₂ /min·kg body mass ^{2/3}	26 \pm 1	16 \pm 2*	20 \pm 1	30 \pm 1
Mitochondrial O ₂ uptake, ngat O ₂ /min ⁻¹ ·mg protein ⁻¹				
State 4	19 \pm 2	16 \pm 1	20 \pm 2	28 \pm 2*
State 3	121 \pm 9	85 \pm 7*	118 \pm 13	163 \pm 13*
RCR	6.4 \pm 0.4	5.9 \pm 0.5	5.9 \pm 0.4	5.8 \pm 0.3
P/O	3.1 \pm 0.1	3.0 \pm 0.1	2.9 \pm 0.1	2.9 \pm 0.1

Data are means \pm SE from 6 to 12 samples. Respiratory control rate (RCR) is defined as the state 3/state 4 respiration rates and P/O as ADP added/O₂ consumed; T₄, thyroxine; T₃, 3,5,3'-thyronine. * $P < 0.05$, with respect to control samples by ANOVA and Dunnett's test.

with anti-iNOS antibodies (13); densitometry analysis of the bands showed a 75% increase in hypothyroidism with respect to controls, which was reverted by T₄ replacement (Fig. 1B). No significant changes were observed in the hyperthyroid samples.

Interestingly, similar effects were observed in gas-trocnemius mitochondria from the four studied groups (Fig. 2). Basal specific activity of skeletal muscle mtNOS was 25% of the liver and increased by the same percentage in hypothyroidism (270%).

To study the specificity of the effects of thyroid hormones on the activity and/or expression of liver mtNOS, we also measured NOS activity in the supernatant from a centrifugation of 7,000 g where endothelial NOS is detected by Western blot analysis (Fig. 3). No significant variations were observed in either the activity or the expression of eNOS in any of the studied groups; in addition, cytosolic iNOS was not detected by immunoblotting (data not shown).

Rat liver mtNOS activity and O₂ uptake in hypothyroidism. To relate increased mtNOS activity to hypothyroid-induced inhibition of O₂ uptake, we measured mitochondrial activities in the presence of L-Arg (0.1–0.3 mM) (Table 2). Addition of L-Arg inhibited the state 3 O₂ uptake more markedly in hypothyroid organelles than in control ones (–23%, $P < 0.05$, and –8%, respectively); in the same conditions, supplementation of the preparations with 10-fold higher concentrations of NOS inhibitor L-NMMA proportionally restored mitochondrial respiratory rates in both groups (Table 2). These variations are relevant, taking into account that effects of NO are more effective at low physiological O₂/NO ratios than at experimentally used 220 μM O₂ (3).

Accordingly, systemic O₂ uptake, state 3 mitochondrial respiratory rate, and L-[³H]citruilline production significantly correlated with serum T₃ levels (r : 0.87, $P < 0.0001$; r : –0.84, $P < 0.0001$; and r : –0.73, $P = 0.003$, respectively) (Fig. 4, A–C); in addition, mtNOS activity correlated as well with state 3 respiratory rate (r : –0.77, $P < 0.0001$) (Fig. 4D) and with systemic O₂ uptake (r : –0.80, $P < 0.0001$).




Fig. 2. Modulation of skeletal muscle mtNOS activity by thyroid status. Experimental procedures and abbreviations as in Fig. 1. Each group consisted of 3 samples measured by duplicate. * $P < 0.05$, by ANOVA and Dunnett's test.




Fig. 3. Endothelial NOS activity and expression in different thyroid states. Supernatant of 7,000 g centrifugation was utilized to study endothelial NOS (eNOS) activity and expression. A: NOS-dependent L-[³H]citruilline formation. Abbreviations as in Fig. 1. B: representative Western blot; C corresponds to eNOS-positive control.


Similar results were obtained when cytochrome oxidase activity was assessed in frozen and thawed rat liver mitochondria. Hypothyroidism was associated with a moderate decrease in cytochrome oxidase activity (–21%) that otherwise was doubled by preincubation with 100 μM L-Arg ($P < 0.05$), an effect mostly reverted by the coincubation with 1 mM aminoguanidine; less evident effects were observed in control samples subjected to the same treatments.

Table 2. Effect of L-arginine on mitochondrial oxygen uptake and cytochrome oxidase activity in hypothyroidism

	Control	Hypothyroidism
State 4, ngat O ₂ /min ⁻¹ ·mg protein ⁻¹		
Without L-Arg	19 ± 2	16 ± 1
+0.3 mM L-Arg	18 ± 2	13 ± 1†
Idem + 3 mM L-NMMA	19 ± 2	15 ± 1
State 3, ngat O ₂ /min ⁻¹ ·mg protein ⁻¹		
Without L-Arg	122 ± 9	92 ± 7*
+0.3 mM L-Arg	113 ± 11	71 ± 2†‡
0.3 mM L-Arg + 3 mM L-NMMA	117 ± 10	85 ± 1
Cytochrome oxidase activity, k·min ⁻¹ ·mg protein ⁻¹		
Without L-Arg	11.7 ± 0.2	9.2 ± 0.2*
+0.1 mM L-Arg	11.3 ± 0.2	7.5 ± 0.4†‡
0.1 mM L-Arg + 1 mM AG	12.2 ± 0.9	8.5 ± 0.2

Data are means ± SE from 4 to 6 samples. AG; aminoguanidine L-NMMA, N^G-monomethyl-L-arginine. * $P < 0.05$, with respect to control; † $P < 0.05$, with respect to control + L-arginine (L-Arg) by Student's t -test; ‡ $P < 0.05$, with respect to hypothyroid group values without L-Arg by one-way ANOVA and Dunnett's test.

Fig. 4. Systemic and mitochondrial O₂ uptake, mtNOS activity, and thyroid status correlations. Data were analyzed by simple linear regression. *A*: systemic O₂ uptake as a function of serum 3,5,3'-thyronine (T₃) levels. Data represent 14 rats from all 4 studied groups. *B*: state 3 liver mitochondrial respiratory rate as a function of serum T₃ levels. Data represent 21 samples measured by duplicate from the 4 studied groups. *C*: mtNOS activity as a function of serum T₃. Data represent 21 samples measured by duplicate from the 4 studied groups. *D*: state 3 rates as a function of mtNOS activity.



DISCUSSION

In this study, changes in thyroid state were followed by parallel variations in systemic and liver mitochondrial O₂ uptake that significantly correlated with serum T₃ levels. Variations in mitochondrial O₂ uptake were observed in both resting state 4 and ADP-stimulated maximal state 3 rates; a similar respiratory control ratio in all tested situations is consistent with a conservation of the coupling of oxidative phosphorylation and electron transfer in the mitochondrial membranes.

On the basis of classic mitochondrial physiology, a clear understanding of the described modulation of cellular respiration by thyroid hormones is not yet complete. In the last years, accumulated experience have clearly evidenced that NO is able to regulate mitochondrial and systemic O₂ uptake in different tissues and in physiological and pathological conditions (1, 6, 24, 30). Accordingly, the results presented here show 1) a clear modulatory effect of thyroid hormones on the expression and activity of rat liver mtNOS and 2) a significant correlation between mtNOS activity and systemic or mitochondrial O₂ uptake. The hypothyroid condition invariably was associated to increased mtNOS protein expression and activity, which were reverted by hormone replacement; moreover, administration of T₄ to normal rats markedly decreased mtNOS activity. In accord to the increased mtNOS activity, isolated mitochondria from the hypothyroid group had even lower O₂ uptake and cytochrome ox-

dase activity in the presence of L-Arg, the universal substrate of NOS (Table 2). Moreover, NOS inhibitor L-NMMA mostly reverted state 3 and 4 O₂ uptake back to the baseline values.

Likewise, these findings are clearly representative of an increased NO production vectorially directed to the mitochondrial matrix. It is noteworthy that NO modulates mitochondrial O₂ by reacting with cytochrome oxidase (2, 23) and that the activity of the enzyme *in vivo* (24) or *in vitro* (25) depends on NO matrix concentration. In this way, it results that the respectively measured 8% and 40% inhibition of mitochondrial O₂ uptake in control and hypothyroid samples treated with L-Arg (Table 2) will follow an increase of matrix steady-state NO concentration from 10 to 50–100 nM (23). Considering the kinetics of NO utilization in liver mitochondria (25) and that in the steady state, NO production and utilization are equalized, 10–100 nM NO should depend on NO production rates of 50 to 250–500 pmol·min⁻¹·mg protein⁻¹, which are in line with the measured mtNOS activity in the different studied conditions (Fig. 1). On the basis of measured mitochondrial O₂ uptake and considering 36 mg of mitochondrial protein/g liver and that 70% of phosphorylating reactions contribute to the resting metabolic rate (28), it emerges that the main contribution of liver metabolic rate to systemic O₂ uptake (basal metabolic rate) was ~5–10% and remained constant in the different thyroid status. Moreover, the increased activity of skeletal muscle mtNOS in hypothyroidism (Fig.

2) may extend thyroid hormone modulation of mtNOS activity and subsequently of mitochondrial O₂ uptake to other organs. Assuming that the increased skeletal muscle mtNOS activity could modify O₂ uptake and considering that muscle represents 40–50% of body mass, it should be expected a contribution of this tissue to the changes observed in basal metabolic rate.

Interestingly, thyroid hormones did not modify the expression or activity of constitutive nonmitochondrial eNOS or induced cytosolic iNOS in liver tissue. This fact confers great specificity to the findings in terms of a compartmentalized response within the mitochondria and with selective effects on O₂ uptake. In addition, these effects should not be viewed as exclusively restricted to a pathological condition as hypothyroidism, but they could be extended to many adaptive conditions associated to changes in tissue T₃ levels. Diminished T₃ levels in peripheral tissues (the “low T₃ syndrome”) result from environmental changes like prolonged cold exposure and adaptation, hibernation, or fasting (14, 15, 32), all accompanied by a significant decrease in O₂ consumption. From this perspective, mtNOS could be preliminarily considered as a final effector of hormonal signaling to adaptively modulate mitochondrial O₂ uptake in different conditions.

In this context, low systemic O₂ uptake in hypothyroidism may depend on NO-dependent inhibition on redox activities, mainly on cytochrome oxidase; however, other causative factors may participate as well. For example, decreased or increased proton leak in hypothyroid or hyperthyroid liver mitochondria had been reported to contribute to O₂ uptake and caloric expenditure (27). These conditions affect both ohmic and nonohmic conductance of mitochondrial membrane (17); at the calculated matrix NO concentrations in hypothyroidism, ~30–40% decrease in resting membrane potential is expected (25). Therefore, intramitochondrial NO could contribute itself to changes in the ohmic segment of proton leak as it decreases proton motive force through the inner membrane by lowering the O₂ uptake.

On the other hand, thyroid hormones (mainly T₃) bound to nuclear thyroid receptors act physiologically as transcription factors of genes encoding the transcription of the components of electron transfer chain-like cytochrome c₁ or ADP-translocase (9, 22); moreover, T₃-unliganded thyroid receptors could even repress synthesis (16). On these bases, it may be considered that 1) changes in the relative concentration of redox enzymes or in the lipid composition of membranes (20) could also contribute to set O₂ uptake and 2) expression and activity of mtNOS could reflect to some extent those structural changes. In this study, the differences in cytochrome oxidase specific activity between control and hypothyroid groups (without L-Arg 21%, with L-Arg 34%, with aminoguanidine 30%) are consistent with the notion that, in hypothyroidism, about a two-third decrease of cytochrome oxidase activity depends on NO effects and one-third on enzyme concentration or on changes in inner membrane cardiolipin content (29).

Finally, expression of uncoupler proteins like UCP-2 could be modified by thyroid hormones, but a correlation with mitochondrial respiration has not been found in the liver yet (20).

Changes in mtNOS activity and/or expression could result from transcriptional, translational, or posttranslational effects of thyroid hormones, likely T₃, on protein biosynthesis. In accord, differences in the increase of expression and activity of mtNOS in hypothyroidism (Fig. 1) suggest that thyroid-dependent changes include both transcriptional and posttranscriptional events. Further observations are required to define the structure of mtNOS, the mechanism of signaling, and the characteristics of the regulatory process in other tissues.

The authors are grateful to Dr. Alberto Boveris for insightful comments on this manuscript and Damián Levisman for technical assistance.

This work was supported by research grants from the University of Buenos Aires (TM047), Subsecretary of Science and Technology, National Ministry of Health (Carrillo-Oñativia), National Agency for Promotion of Scientific and Technologic Development (PICT 02372), and the Perez Compañc Foundation (Buenos Aires, Argentina).

REFERENCES

1. **Boczkowski J, Lisdero C, Lanone S, Samb A, Carreras MC, Boveris A, Aubier, and Poderoso JJ.** Endogenous peroxynitrite mediates mitochondrial dysfunction in rat diaphragm during endotoxemia. *FASEB J* 13: 1637–1647, 1999.
2. **Boveris A, Oshino N, and Chance B.** The cellular production of hydrogen peroxide. *Biochem J* 128: 617–630, 1972.
3. **Boveris AA, Costa L, Cadenas E, and Poderoso JJ.** Regulation of mitochondrial respiration by adenosine phosphate, oxygen, and nitric oxide. *Methods Enzymol* 301: 188–198, 1999.
4. **Boveris A and Poderoso JJ.** Regulation of oxygen metabolism by nitric oxide. In: *Nitric Oxide, Biology and Pathobiology*, edited by Ignarro L. San Diego, CA: Academic, 2000, p. 355–368.
5. **Brand MD, Chien L-F, Ainscow EK, Rolfe DFS, and Porter RK.** The causes and functions of mitochondrial proton leak. *Biochim Biophys Acta* 1187: 132–139, 1994.
6. **Brown GC and Cooper CE.** Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. *FEBS Lett* 356: 295–298, 1994.
7. **Brown GC.** Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. *FEBS Lett* 369: 136–139, 1995.
8. **Cleeter MWJ, Cooper JM, Darley-Usmar VM, Moncada S, and Schapira AHV.** Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. *FEBS Lett* 345: 50–54, 1994.
9. **Dummler K, Muller S, Seitz HJ, Dummler K, Muller S, and Seitz HJ.** Regulation of adenine nucleotide translocase and glycerol 3-phosphate dehydrogenase expression by thyroid hormones in different rat tissues. *Biochem J* 317: 913–918, 1996.
10. **Estabrook RW.** Mitochondrial respiratory control and the polarographic measurements of ADP:O ratios. *Methods Enzymol* 10: 41–47, 1967.
11. **Fernández V, Cornejo P, Tapia G, and Videla LA.** Influence of hyperthyroidism on the activity of liver nitric oxide synthase in the rat. *Nitric Oxide* 1: 463–468, 1997.
12. **Ghafourifar P and Richter C.** Nitric oxide synthase activity in mitochondria. *FEBS Lett* 418: 291–296, 1997.
13. **Giulivi C, Poderoso JJ, and Boveris A.** Production of nitric oxide by mitochondria. *J Biol Chem* 273: 11038–11043, 1998.
14. **Goglia F, Liverini G, De Leo T, and Barletta A.** Thyroid state and mitochondrial population during cold exposure. *Pflügers Arch* 396: 49–53, 1983.

15. **Goglia F, Liverini G, Lanni A, and Barletta A.** Mitochondrial DNA, RNA and protein synthesis in normal, hypothyroid and mildly hyperthyroid rat liver during cold exposure. *Mol Cell Endocrinol* 55: 141–147, 1988.
16. **Goglia F, Moreno M, and Lanni A.** Action of thyroid hormones at the cellular level: the mitochondrial target. *FEBS Lett* 452: 115–120, 1999.
17. **Hafner RP, Nobes CD, Mc Gown AD, and Brand MD.** Altered relationship between protonmotive force and respiration rate in nonphosphorylating liver mitochondria isolated from rats of different thyroid hormone status. *Eur J Biochem* 178: 511–518, 1998.
18. **Hovius R, Lambechts H, Nicolay K, and de Kruijff V.** Improved methods to isolate and subfractionate rat liver mitochondria lipid composition of the inner and outer membrane. *Biochim Biophys Acta* 1021: 217–226, 1990.
19. **Hulbert AJ, Auger ML, and Raison JK.** The influence of thyroid hormones on the structure and function of mitochondrial membranes. *Biochim Biophys Acta* 455: 597–601, 1976.
20. **Jekabsons MB, Gregoire FM, Schonfeld-Warden NA, Warden CH, and Horwitz BA.** T₃ stimulates resting metabolism and UCP-2 and UCP-3 mRNA but not nonphosphorylating mitochondrial respiration in mice. *Am J Physiol Endocrinol Metab* 277: E380–E389, 1999.
21. **Knowles RG and Salter M.** Measurement of nitric oxide synthase activity by the conversion of radiolabeled arginine to citrulline using ion exchange separation. In: *Methods in Molecular Biology (Nitric Oxide Protocols)*, edited by Titheradge MA. Totowa, NJ: Humana, 1998, vol. 100, p. 67–73.
22. **Pillar TM and Seitz HJ.** Thyroid hormone and gene expression in the regulation of mitochondrial respiratory function. *Eur J Endocrinol* 136: 231–239, 1997.
23. **Poderoso JJ, Carreras MC, Lisdero C, Riobó N, Schöpfer F, and Boveris A.** Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. *Arch Biochem Biophys* 328: 85–92, 1996.
24. **Poderoso JJ, Peralta J, Lisdero C, Carreras MC, Radisic M, Schöpfer F, Cadenas E, and Boveris A.** Nitric oxide regulates oxygen uptake and hydrogen peroxide release by the isolated beating rat heart. *Am J Physiol Cell Physiol* 274: C112–C119, 1998.
25. **Poderoso JJ, Lisdero C, Schöpfer F, Riobó N, Carreras MC, Cadenas E, and Boveris A.** The regulation of mitochondrial oxygen uptake by redox reactions involving nitric oxide and ubiquinol. *J Biol Chem* 274: 37709–37716, 1999.
26. **Reitman ML, He Y, and Gong D-W.** Thyroid hormone and other regulators of uncoupling proteins. *Int J Obes* 23: S56–S59, 1999.
27. **Rolfe DF, Newman JM, Buckingham JA, Clark MG, and Brand MD.** Contribution of mitochondrial proton leak to respiration rate in working skeletal muscle and liver and to SMR. *Am J Physiol Cell Physiol* 276: C692–C699, 1999.
28. **Rolfe DFS and Brown GC.** Cellular energy utilization and molecular origin of standard metabolic rate in mammals. *Physiol Rev* 77: 731–758, 1997.
29. **Schlame M and Hostetler KY.** Cardiolipin synthase from mammalian mitochondria. *Biochim Biophys Acta* 1348: 207–213, 1997.
30. **Shen W, Xu X, Ochoa M, Zhao G, Wolin M, and Hintze TH.** Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. *Circ Res* 75: 1086–1095, 1994.
31. **Smith L.** *Methods of Biochemical Analysis*, edited by Glick D. New York: Wiley Interscience, 1998, vol II, p. 427.
32. **Sul HS and Wand D.** Nutritional and hormonal regulation of enzymes in fat synthesis: studies of fatty acid synthase and mitochondrial glycerol-3-phosphate acyltransferase gene transcription. *Annu Rev Nutr* 18: 331–351, 1998.
33. **Takehara Y, Kanno T, Yoshioka T, Inoue M, and Utsumi K.** Oxygen-dependent regulation of mitochondrial energy metabolism by nitric oxide. *Arch Biochem Biophys* 323: 27–32, 1995.
34. **Zaninovich AA, Rebagliati I, Raíces M, Ricci C, and Haggmuller K.** Effects of thyroxine on rat brown fat and muscle thermogenesis in the cold. *Endocr Res* 26: 231–245, 2000.